Dihexa draws attention from the cognitive-enhancement and neuroregeneration edge of the peptide world.
FDA reports no identified human exposure data, and its full committee review is still ahead.
What a visitor should know.
Technical details: aliases, tracked claims, and data record
2 names in this peptide family.
Dihexa acetate is the nominated substance; shorthand references to Dihexa are retained as aliases rather than assumed to be identical products.
4 evidence questions.
Human benefitNo identified human exposureDoes Dihexa acetate have established human clinical benefit for uses to be specified in forthcoming meeting materials?
FDA approvalNo FDA approval identifiedIs Dihexa acetate FDA approved?
503A statusRegulatory recordIs Dihexa acetate on FDA's final 503A Bulks List or generally permitted because of committee activity?
Identity transferIdentity-sensitiveAre every product, alias, form, and related compound labeled Dihexa acetate automatically interchangeable?
See every Dihexa acetate evidence question →Open the machine-readable record ↗FDA placed the meeting before the end of February 2027
Dihexa acetate remains one of five substances on the agenda. FDA has not yet posted the exact meeting date or compound-specific briefing materials.
The review has a public time window.
No committee recommendation or FDA decision has occurred.
How the FDA record developed.
This timeline separates early nominations and scientific reviews from committee votes and final FDA decisions.
FDA placed the meeting before the end of February 2027
Dihexa acetate remains one of five substances on the agenda. FDA has not yet posted the exact meeting date or compound-specific briefing materials.
Read the source ↗FDA announced a future advisory review
Dihexa acetate was named among five bulk drug substances scheduled for committee consideration.
Read the source ↗What has actually been studied?
Human studies appear on the left. Animal, cell, and laboratory studies appear on the right because they cannot establish that a treatment works in people.
FDA says the advisory review will happen before the end of February 2027. It reports no identified human exposure data.
Read the FDA review ↗Preclinical evidence will be classified when FDA posts the meeting briefing materials.
Dihexa improved several cognitive and tissue measures in an Alzheimer's disease mouse model. FDA reports no identified human exposure data for dihexa acetate.
Read the study on PubMed ↗Important unknowns.
- FDA has identified limited or absent human safety information for the nominated use context.
- Peptide impurities, aggregation, immunogenicity, or API characterization may be material concerns.
- Compound-specific FDA concerns are linked in the source record.
These are evidence and regulatory uncertainties, not an individualized assessment of whether a treatment is appropriate.
Read the original sources.
Technical change history and comparison data
2 dated changes. 2 comparison groups.
These records show what each source added and whether it changed Peplyst's public conclusion.